Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Gene Variant Descriptions||FLT3 exon 19, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 19 of the FLT3 gene.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon19||acute myeloid leukemia||sensitive||Cytarabine + Daunorubicin + Midostaurin||Guideline||Actionable||Rydapt (midostaurin), in combination with Cerubidine (daunorubicin) and Cytosar-U (cytarabine), is included in guidelines for patients with acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).||detail...|
|FLT3 exon19||acute myeloid leukemia||sensitive||Gilteritinib||Guideline||Actionable||Xospata (gilteritinib) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a mutation in the FLT3 tyrosine kinase domain (exons 14-23) (NCCN.org).||detail...|
|Molecular Profile||Protein Effect||Treatment Approaches|